Importantly, the dependence of DNA replication or proliferation pathways in supporting tumor cell malignancy, along with several mesenchyme-related pathways contributing to the survival of tumor cells in metastatic nodes, makes FAK-activated metabolites attractive targets for intervention in both tumors in primary and metastatic nodes. Here, PTK2 is linked to neoplasm.